https://www.selleckchem.com/pr....oducts/sumatriptan.h
Food and Drug Administration (FDA) rules restrict pharmaceutical manufacturers from promoting drugs for non-FDA-approved (off-label) indications. When manufacturers violate this rule, it has in many cases led to unsafe prescribing. However, in 2012, a federal circuit court ruled in United States v. Caronia that truthful off-label promotion was protected under the First Amendment, threatening government enforcement in this area. The authors extracted cases from the WestLawNext database that mentioned Caronia from 2012 to 2019. They c
Like
Comment
Share
